Epigenetics in Cancer

Dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible, and thus make a promising therapeutic target.

Epigenetics in Cancer Products Targets

Products for Epigenetics in Cancer - Page 8

Cat.No. Product Name Information/Activity
BCC5625 UNC 2400 1433200-49-7
BCC5626 WDR5 0103 WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with Kd of 450 nM.
BCC2445 UNC 926 hydrochloride UNC-926 is a methyl-lysine (Kme) reader domain inhibitor; inhibits L3MBTL1 with an IC50 of 3.9 μM.
BCC2212 INO-1001 3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP with IC50 of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.
BCC2208 Iniparib (BSI-201) Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
BCC2449 BYK 204165 BYK204165 is a potent and selective PARP1 inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC50 of 7.35 (pKi=7.05), and murine PARP-2 (mPARP-2) with a pIC50 of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1.
BCC2450 BYK 49187 PARP-1 and PARP-2 inhibitor
BCC2451 DR 2313 PARP-1 and PARP-2 inhibitor
BCC2452 EB 47 Potent PARP-1 inhibitor
BCC2448 4-HQN 4(3H)-Quinazolinone is a building block in chemical synthesis. Biologically active nitrogen heterocyclic compounds. Possesses a wide spectrum of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities.